Castle Biosciences (CSTL) Equity Average (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Equity Average data on file, last reported at $466.1 million in Q1 2026.

• Quarterly Equity Average rose 4.03% year-over-year to $466.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $466.1 million (up 4.03% YoY) and the FY2025 annual result came in at $463.4 million, up 9.4% from the prior year.
• Equity Average fell to $466.1 million in Q1 2026 per CSTL's latest filing, from $469.0 million in the prior quarter.
• The five-year high for Equity Average was $469.0 million in Q4 2025, with the low at $382.0 million in Q2 2023.
• Average Equity Average over 5 years is $421.4 million, with a median of $413.2 million recorded in 2024.
• Year-over-year, Equity Average retreated 8.23% in 2023 and advanced 15.42% in 2024.
• Castle Biosciences' Equity Average stood at $405.3 million in 2022, then dropped by 4.14% to $388.5 million in 2023, then increased by 15.42% to $448.4 million in 2024, then grew by 4.57% to $469.0 million in 2025, then fell by 0.6% to $466.1 million in 2026.
• Business Quant data shows CSTL's Equity Average at $466.1 million in Q1 2026, $469.0 million in Q4 2025, and $461.2 million in Q3 2025.